Association of autosomal dominant polycystic kidney disease with cardiovascular disease: a US-National Inpatient Perspective.
Autosomal dominant polycystic kidney disease
Cardiovascular disease
Chronic kidney disease
Mortality
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
07
01
2022
accepted:
11
02
2022
pubmed:
26
2
2022
medline:
22
6
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Data on the epidemiology of cardiovascular diseases (CVD) in patients with autosomal dominant polycystic kidney disease (ADPKD) are limited. In this study, we assess the prevalence of CVD in patients with ADPKD and evaluate associations between these two entities. Using the National Inpatient Sample database, we identified 71,531 hospitalizations among adults aged ≥ 18 years with ADPKD, from 2006 to 2014 and collected relevant clinical data. The prevalence of CVD in the study population was 42.6%. The most common CVD were ischemic heart diseases (19.3%), arrhythmias (14.2%), and heart failure (13.1%). The prevalence of CVD increased with the severity of renal dysfunction (RD). We found an increase in hospitalizations of patients with ADPKD and CVD over the years (p The prevalence of CVD is high among patients with ADPKD, and the most important risk factor associated with CVD is severity of RD. We found an increase in the trend of hospitalizations of patients with ADPKD associated with increased risk of AF, PHN, NICM, and hemorrhagic stroke. History of CVD is the strongest predictor of mortality among patients with ADPKD.
Identifiants
pubmed: 35212882
doi: 10.1007/s10157-022-02200-5
pii: 10.1007/s10157-022-02200-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-668Informations de copyright
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Références
Igarashi P, Somlo S. Polycystic kidney disease. J Am Soc Nephrol. 2007;18(5):1371–3.
doi: 10.1681/ASN.2007030299
Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76(2):149–68.
doi: 10.1038/ki.2009.128
Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet (London, England). 2007;369(9569):1287–301.
doi: 10.1016/S0140-6736(07)60601-1
Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al. Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA Registry. Nephrol Dialysis Transp. 2014;29(Suppl 4):iv15–25.
doi: 10.1093/ndt/gfu017
Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant polycystic kidney disease (ADPKD): a meta-analysis of European literature and prevalence evaluation in the Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS ONE. 2018;13(1): e0190430.
doi: 10.1371/journal.pone.0190430
Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009;5(4):221–8.
doi: 10.1038/nrneph.2009.13
Reed-Gitomer B. Autosomal dominant polycystic kidney disease: cardiovascular complications. Curr Hypertens Rev. 2013;9(1):1.
doi: 10.2174/1573402111309010001
Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet (London, England). 2019;393(10174):919–35.
doi: 10.1016/S0140-6736(18)32782-X
Helal I, Reed B, Mettler P, Mc Fann K, Tkachenko O, Yan XD, et al. Prevalence of cardiovascular events in patients with autosomal dominant polycystic kidney disease. Am J Nephrol. 2012;36(4):362–70.
doi: 10.1159/000343281
Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1995;5(12):2048–56.
doi: 10.1681/ASN.V5122048
(HCUP) HCaUP. Overview of the National (Nationwide) Inpatient Sample (NIS). Rockville, MD: Agency for Healthcare Research and Quality. http://www.hcup-us.ahrq.gov/nisoverview : Healthcare Cost and Utilization Project (HCUP); 2019 [Available from: http://www.hcup-us.ahrq.gov/nisoverview.jsp .
HCUP. Trend Weights for HCUP NIS Data May, 2015. Available from: https://www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jsp .
Gupta T, Paul N, Kolte D, Harikrishnan P, Khera S, Aronow WS, et al. Association of chronic renal insufficiency with in-hospital outcomes after percutaneous coronary intervention. J Am Heart Assoc. 2015;4(6): e002069.
doi: 10.1161/JAHA.115.002069
Kumar G, Sakhuja A, Taneja A, Majumdar T, Patel J, Whittle J, et al. Pulmonary embolism in patients with CKD and ESRD. Clin J Am Soc Nephrol. 2012;7(10):1584–90.
doi: 10.2215/CJN.00250112
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al. Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015;88(1):17–27.
doi: 10.1038/ki.2015.59
Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2012;16(4):622–8.
doi: 10.1007/s10157-012-0611-9
Quan H, Li B, Saunders LD, Parsons GA, Nilsson CI, Alibhai A, et al. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually coded database. Health Serv Res. 2008;43(4):1424–41.
doi: 10.1111/j.1475-6773.2007.00822.x
Khera R, Angraal S, Couch T, Welsh JW, Nallamothu BK, Girotra S, et al. Adherence to methodological standards in research using the National Inpatient sample. JAMA. 2017;318(20):2011–8.
doi: 10.1001/jama.2017.17653
Haukoos JS, Lewis RJ. The propensity score. JAMA. 2015;314(15):1637–8.
doi: 10.1001/jama.2015.13480
Dugoff EH, Schuler M, Stuart EA. Generalizing observational study results: applying propensity score methods to complex surveys. Health Serv Res. 2014;49(1):284–303.
doi: 10.1111/1475-6773.12090
Harris PC, Torres VE. Polycystic kidney disease, autosomal dominant. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews((R)). Seattle (WA): University of Washington, Seattle University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.; 1993
Ecder T. Cardiovascular complications in autosomal dominant polycystic kidney disease. Curr Hypertens Rev. 2013;9(1):2–11.
doi: 10.2174/1573402111309010002
Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. New Eng J Med. 2008;359(14):1477–85.
doi: 10.1056/NEJMcp0804458
Speer T, Schunk SJ, Fliser D. [Chronic kidney disease-a cardiovascular high-risk constellation]. Der Internist. 2019.
Lai S, Mastroluca D, Matino S, Panebianco V, Vitarelli A, Capotosto L, et al. Early markers of cardiovascular risk in autosomal dominant polycystic kidney disease. Kidney Blood Press Res. 2017;42(6):1290–302.
doi: 10.1159/000486011
Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med. 1990;323(16):1091–6.
doi: 10.1056/NEJM199010183231602
Gabow PA, Chapman AB, Johnson AM, Tangel DJ, Duley IT, Kaehny WD, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1990;38(6):1177–80.
doi: 10.1038/ki.1990.330
Graham PC, Lindop GB. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int. 1988;33(6):1084–90.
doi: 10.1038/ki.1988.115
Chapman AB, Johnson AM, Rainguet S, Hossack K, Gabow P, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 1997;8(8):1292–7.
doi: 10.1681/ASN.V881292
Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41(5):1311–9.
doi: 10.1038/ki.1992.195
Perrone RD, Ruthazer R, Terrin NC. Survival after end-stage renal disease in autosomal dominant polycystic kidney disease: contribution of extrarenal complications to mortality. Am J Kidney Dis. 2001;38(4):777–84.
doi: 10.1053/ajkd.2001.27720
Shaw C, Simms RJ, Pitcher D, Sandford R. Epidemiology of patients in England and Wales with autosomal dominant polycystic kidney disease and end-stage renal failure. Nephrol Dial Transp. 2014;29(10):1910–8.
doi: 10.1093/ndt/gfu087
Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2009;20(9):1888–93.
doi: 10.1681/ASN.2008080882
Martinez-Vea A, Valero FA, Bardaji A, Gutierrez C, Broch M, Garcia C, et al. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol. 2000;20(3):193–200.
doi: 10.1159/000013583
Paavola J, Schliffke S, Rossetti S, Kuo IY, Yuan S, Sun Z, et al. Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy. J Mol Cell Cardiol. 2013;58:199–208.
doi: 10.1016/j.yjmcc.2013.01.015
Kuo IY, Kwaczala AT, Nguyen L, Russell KS, Campbell SG, Ehrlich BE. Decreased polycystin 2 expression alters calcium-contraction coupling and changes β-adrenergic signaling pathways. Proc Natl Acad Sci USA. 2014;111(46):16604–9.
doi: 10.1073/pnas.1415933111
de Chickera S, Akbari A, Levin A, Tang M, Brown P, Djurdev O, et al. The risk of adverse events in patients with polycystic kidney disease with advanced chronic kidney disease. Can J Kidney Health Dis. 2018;5:2054358118774537.
doi: 10.1177/2054358118774537
Namli S, Oflaz H, Turgut F, Alisir S, Tufan F, Ucar A, et al. Improvement of endothelial dysfunction with simvastatin in patients with autosomal dominant polycystic kidney disease. Ren Fail. 2007;29(1):55–9.
doi: 10.1080/08860220601038892
Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, et al. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014;9(5):889–96.
doi: 10.2215/CJN.08350813
Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol. 2007;293(3):F854–9.
doi: 10.1152/ajprenal.00059.2007
Gile RD, Cowley BD, Gattone VH, O’Donnell MP, Swan SK, Grantham JJ. Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis. 1995;26(3):501–7.
doi: 10.1016/0272-6386(95)90497-2
Abbott KC, Agodoa LY. Polycystic kidney disease in patients on the renal transplant waiting list: trends in hematocrit and survival. BMC Nephrol. 2002;3:7.
doi: 10.1186/1471-2369-3-7
Ushio Y, Kataoka H, Sato M, Manabe S, Watanabe S, Akihisa T, et al. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Clin Exp Nephrol. 2020;24(6):500–8.
doi: 10.1007/s10157-020-01856-1
Patel N, Kalra R, Doshi R, Arora H, Bajaj NS, Arora G, et al. Hospitalization rates, prevalence of cardiovascular manifestations, and outcomes associated with sarcoidosis in the United States. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.117.007844 .
doi: 10.1161/JAHA.117.007844
pubmed: 30571485
pmcid: 6405705